INVESTORS

Press Releases


Press Releases

September 27, 2021
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 27, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that Michael Amoroso has been named as the...
September 2, 2021
Precision Gains Access to Tiziana’s Anti-CD3 Antibody, Foralumab, to Evaluate as a Lymphodepletion Agent with its Allogeneic CAR T Portfolio DURHAM, N.C. , NEW YORK & LONDON --(BUSINESS WIRE)--Sep. 2, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company...
Displaying 1 - 10 of 37